This study also demonstrated the potential of targeting SORL1 with an antibody blocker or targeting FGFR4 with a small molecule inhibitor as new strategies to improve the response to chemotherapy in patients with recurrent and resistant ovarian cancer. This evidence concerns the gene FGFR4 and ovarian cancer.